Allogene Therapeutics (ALLO) Short Interest Ratio & Short Volume $2.21 +0.10 (+4.74%) (As of 11/22/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Allogene Therapeutics Short Interest DataAllogene Therapeutics (ALLO) has a short interest of 37.04 million shares, representing 26.73% of the float (the number of shares available for trading by the public). This marks a -5.80% decrease in short interest from the previous month. The short interest ratio (days to cover) is 18.7, indicating that it would take 18.7 days of the average trading volume of 2.66 million shares to cover all short positions.Current Short Interest37,040,000 sharesPrevious Short Interest39,320,000 sharesChange Vs. Previous Month-5.80%Dollar Volume Sold Short$94.64 millionShort Interest Ratio18.7 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares209,670,000 sharesFloat Size138,570,000 sharesShort Percent of Float26.73%Today's Trading Volume1,456,823 sharesAverage Trading Volume2,660,311 sharesToday's Volume Vs. Average55% Short Selling Allogene Therapeutics? Sign up to receive the latest short interest report for Allogene Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartALLO Short Interest Over TimeALLO Days to Cover Over TimeALLO Percentage of Float Shorted Over Time Ad Chaikin Analytics50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies. You can watch for it for free, right here. Allogene Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/202437,040,000 shares $94.64 million -5.8%26.7%18.7 $2.56 10/15/202439,320,000 shares $106.56 million +2.1%28.5%21.7 $2.71 9/30/202438,510,000 shares $107.83 million -1.7%28.2%18.3 $2.80 9/15/202439,190,000 shares $116.00 million +0.6%28.7%17 $2.96 8/31/202438,940,000 shares $102.41 million -0.7%28.5%15.8 $2.63 8/15/202439,230,000 shares $90.23 million +3.9%28.7%14.5 $2.30 Get the Latest News and Ratings for ALLO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/202437,750,000 shares $110.99 million -12.7%27.6%12.9 $2.94 7/15/202443,230,000 shares $128.83 million +4.5%31.6%14.7 $2.98 6/30/202441,380,000 shares $96.42 million -4.4%30.3%15.3 $2.33 6/15/202443,280,000 shares $101.71 million +6.7%31.7%17.1 $2.35 5/31/202440,570,000 shares $101.43 million +11.4%33.5%16.2 $2.50 5/15/202436,430,000 shares $108.56 million +7.6%30.1%15.7 $2.98 4/30/202433,870,000 shares $93.48 million +8.0%32.0%15.5 $2.76 4/15/202431,360,000 shares $111.33 million +2.4%30.0%13.9 $3.55 3/31/202430,620,000 shares $136.87 million +10.3%29.3%11.7 $4.47 3/15/202427,750,000 shares $129.32 million +11.0%26.6%10 $4.66 2/29/202425,010,000 shares $122.80 million +6.7%24.1%8.3 $4.91 2/15/202423,450,000 shares $116.31 million +1.6%22.6%7.7 $4.96 1/31/202423,090,000 shares $81.28 million -23.6%22.2%7.4 $3.52 1/15/202430,210,000 shares $97.28 million -3.5%28.5%10.3 $3.22 12/31/202331,320,000 shares $100.54 million -6.7%29.6%11.9 $3.21 12/15/202333,550,000 shares $90.92 million +5.3%31.7%14.3 $2.71 11/30/202331,860,000 shares $74.87 million -1.5%30.1%16.8 $2.35 11/15/202332,340,000 shares $87.96 million -5.0%30.6%18.9 $2.72 10/31/202334,030,000 shares $95.96 million +10.7%32.2%22 $2.82 10/15/202330,730,000 shares $98.03 million -10.0%29.2%18 $3.19 9/30/202334,130,000 shares $108.19 million +2.1%32.2%19 $3.17 9/15/202333,420,000 shares $130.00 million +4.1%31.5%16.2 $3.89 8/31/202332,110,000 shares $124.91 million -2.0%30.3%12.4 $3.89 8/15/202332,770,000 shares $133.70 million -13.6%30.9%12.5 $4.08 7/31/202337,910,000 shares $188.03 million -8.1%39.4%14.3 $4.96 7/15/202341,260,000 shares $204.65 million +8.1%53.9%15.3 $4.96 6/30/202338,180,000 shares $189.75 million +1.7%49.9%14.1 $4.97 6/15/202337,560,000 shares $186.67 million -6.2%49.1%15.1 $4.97 5/31/202340,030,000 shares $210.16 million -1.4%52.1%20.4 $5.25 5/15/202340,590,000 shares $273.58 million -0.2%52.8%19.6 $6.74 4/30/202340,650,000 shares $220.73 million -1.4%53.3%20.3 $5.43 4/15/202341,220,000 shares $205.69 million +0.5%54.5%22.2 $4.99 3/31/202341,010,000 shares $202.59 million +3.0%54.3%22.5 $4.94 3/15/202339,800,000 shares $225.27 million +8.0%49.6%20.9 $5.6650-year Wall Street legend: “Sell this tech stock NOW” (Ad)Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies. You can watch for it for free, right here. 2/28/202336,860,000 shares $234.06 million +4.9%46.0%19.4 $6.35 2/15/202335,140,000 shares $254.06 million +2.1%44.0%18.4 $7.23 1/31/202334,410,000 shares $265.65 million +0.7%43.1%18 $7.72 1/15/202334,160,000 shares $241.17 million +2.2%42.7%18.1 $7.06 12/30/202233,430,000 shares $210.27 million +9.5%41.8%18 $6.29 12/15/202230,530,000 shares $216.15 million +0.2%38.2%16 $7.08 11/30/202230,470,000 shares $300.43 million -3.2%38.1%16.5 $9.86 11/15/202231,460,000 shares $311.45 million +1.6%39.3%18.2 $9.90 10/31/202230,960,000 shares $318.89 million +3.0%39.3%18.3 $10.30 10/15/202230,050,000 shares $305.91 million +8.9%38.3%18 $10.18 9/30/202227,590,000 shares $297.97 million +24.2%35.2%16 $10.80 9/15/202222,220,000 shares $311.08 million +0.9%28.3%12.8 $14.00 8/31/202222,020,000 shares $301.89 million -2.4%28.1%12 $13.71 8/15/202222,570,000 shares $390.01 million +0.8%28.8%11.6 $17.28 7/31/202222,400,000 shares $290.75 million -0.1%28.6%10.9 $12.98 7/15/202222,430,000 shares $287.33 million -0.3%28.6%10.2 $12.81 6/30/202222,490,000 shares $256.39 million +2.0%28.5%10.5 $11.40 6/15/202222,060,000 shares $212.22 million +9.5%28.0%10.8 $9.62 5/31/202220,150,000 shares $159.79 million +13.9%25.7%10.8 $7.93 5/15/202217,690,000 shares $127.90 million -0.4%22.5%9.6 $7.23 4/30/202217,760,000 shares $148.30 million -1.7%24.3%10.4 $8.35 4/15/202218,060,000 shares $149.00 million +18.6%24.8%11.4 $8.25 3/31/202215,230,000 shares $138.75 million +4.8%16.1%8.9 $9.11 3/15/202214,540,000 shares $113.41 million +18.7%19.8%8.6 $7.80 2/28/202212,250,000 shares $112.09 million +16.9%16.7%7.5 $9.15 2/15/202210,480,000 shares $106.79 million +10.0%14.3%6.8 $10.19 1/31/20229,530,000 shares $109.12 million +5.1%14.3%6.6 $11.45 1/15/20229,070,000 shares $120.45 million +19.7%13.6%6.2 $13.28 12/31/20217,580,000 shares $113.09 million +34.9%11.4%4.1 $14.92 12/15/20215,620,000 shares $86.38 million +4.7%8.4%2.7 $15.37 11/30/20215,370,000 shares $99.29 million -5.3%8.1%2.9 $18.49 11/15/20215,670,000 shares $106.99 million +19.6%8.5%3.1 $18.87 10/29/20214,740,000 shares $81.72 million +0.2%7.1%2.6 $17.24 10/15/20214,730,000 shares $77.95 million -40.7%7.1%2.8 $16.48 9/30/20217,980,000 shares $205.09 million +1.7%12.0%6.7 $25.70 9/15/20217,850,000 shares $196.25 million -6.0%11.8%9.5 $25.00 8/31/20218,350,000 shares $199.15 million -0.4%11.7%9.4 $23.85 8/13/20218,380,000 shares $179.67 million -9.6%11.7%7.5 $21.44 7/30/20219,270,000 shares $203.48 million -2.2%13.0%7.1 $21.95 7/15/20219,480,000 shares $211.88 million +0.2%13.3%7.1 $22.35 6/30/20219,460,000 shares $246.72 million +15.5%13.3%7 $26.08 6/15/20218,190,000 shares $205.00 million +3.0%11.5%7 $25.03 5/28/20217,950,000 shares $204.32 million -3.4%11.3%6.8 $25.70 5/14/20218,230,000 shares $221.72 million +13.5%11.6%7.8 $26.94 4/30/20217,250,000 shares $231.86 million -12.7%10.2%8.5 $31.98 4/15/20218,300,000 shares $266.85 million -3.8%11.9%10.1 $32.15 3/31/20218,630,000 shares $288.50 million -16.1%12.4%10 $33.43 3/15/202110,290,000 shares $395.96 million -10.9%14.6%11.1 $38.48 2/26/202111,550,000 shares $378.72 million +4.2%16.5%12.4 $32.79 2/12/202111,080,000 shares $381.15 million -4.0%15.8%12.6 $34.4050-year Wall Street legend: “Sell this tech stock NOW” (Ad)Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies. You can watch for it for free, right here. 1/29/202111,540,000 shares $398.25 million -15.9%16.8%12.8 $34.51 1/15/202113,720,000 shares $426.28 million +5.2%20.1%14.8 $31.07 12/31/202013,040,000 shares $347.39 million +15.7%19.1%15.4 $26.64 12/15/202011,270,000 shares $315.56 million +5.8%16.5%13.8 $28.00 11/30/202010,650,000 shares $335.69 million +0.7%15.7%14.1 $31.52 11/15/202010,580,000 shares $339.30 million +5.1%15.6%15.4 $32.07 10/30/202010,070,000 shares $358.19 million -0.5%14.9%15.5 $35.57 10/15/202010,120,000 shares $436.88 million -2.3%15.0%17.2 $43.17 9/30/202010,360,000 shares $390.68 million +1.5%15.4%17.7 $37.71 9/15/202010,210,000 shares $363.58 million -5.0%15.1%16.3 $35.61 8/31/202010,750,000 shares $383.24 million +0.6%15.9%16.6 $35.65 8/14/202010,690,000 shares $394.78 million -2.8%15.9%11.9 $36.93 7/31/202011,000,000 shares $403.37 million -8.8%16.7%9.6 $36.67 7/15/202012,060,000 shares $501.58 million -10.1%18.4%10.1 $41.59 6/30/202013,420,000 shares $561.76 million +16.8%23.3%10.9 $41.86 6/15/202011,490,000 shares $482.69 million -13.3%20.2%9.5 $42.01 5/29/202013,250,000 shares $638.12 million -1.6%23.6%10.9 $48.16 5/15/202013,460,000 shares $604.49 million +2.2%26.5%12.9 $44.91 4/30/202013,170,000 shares $380.61 million -6.7%26.0%17.4 $28.90 4/15/202014,110,000 shares $362.20 million +6.9%27.5%19.9 $25.67 3/31/202013,200,000 shares $390.72 million -0.3%26.1%19.8 $29.60 3/13/202013,240,100 shares $300.42 million +2.2%40.9%16.7 $22.69 2/28/202012,950,000 shares $246.18 million -0.5%40.0%19.8 $19.01 2/14/202013,010,000 shares $338.00 million +1.3%26.6%20.3 $25.98 1/31/202012,850,000 shares $327.03 million -1.4%26.3%21.1 $25.45 1/15/202013,030,000 shares $305.16 million +1.6%26.6%22.2 $23.42 12/31/201912,830,000 shares $300.35 million +9.6%26.2%23.8 $23.41 ALLO Short Interest - Frequently Asked Questions What is Allogene Therapeutics' current short interest? Short interest is the volume of Allogene Therapeutics shares that have been sold short but have not yet been closed out or covered. As of October 31st, traders have sold 37,040,000 shares of ALLO short. 26.73% of Allogene Therapeutics' shares are currently sold short. Learn More on Allogene Therapeutics' current short interest. What is a good short interest ratio for Allogene Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ALLO shares currently have a short interest ratio of 19.0. Learn More on Allogene Therapeutics's short interest ratio. What is a good short interest percentage for Allogene Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 26.73% of Allogene Therapeutics' floating shares are currently sold short. Is Allogene Therapeutics' short interest increasing or decreasing? Allogene Therapeutics saw a drop in short interest in the month of October. As of October 31st, there was short interest totaling 37,040,000 shares, a drop of 5.8% from the previous total of 39,320,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Allogene Therapeutics' float size? Allogene Therapeutics currently has issued a total of 209,670,000 shares. Some of Allogene Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Allogene Therapeutics currently has a public float of 138,570,000 shares. How does Allogene Therapeutics' short interest compare to its competitors? 26.73% of Allogene Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Allogene Therapeutics: Fate Therapeutics, Inc. (13.96%), bluebird bio, Inc. (24.54%), Recursion Pharmaceuticals, Inc. (27.97%), Immunocore Holdings plc (16.38%), Neumora Therapeutics, Inc. (17.06%), BioCryst Pharmaceuticals, Inc. (10.06%), Novavax, Inc. (24.96%), Mesoblast Limited (1.22%), Vir Biotechnology, Inc. (6.44%), LENZ Therapeutics, Inc. (9.22%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Allogene Therapeutics stock? Short selling ALLO is an investing strategy that aims to generate trading profit from Allogene Therapeutics as its price is falling. ALLO shares are trading up $0.10 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Allogene Therapeutics? A short squeeze for Allogene Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ALLO, which in turn drives the price of the stock up even further. How often is Allogene Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALLO, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies Fate Therapeutics Short Squeeze bluebird bio Short Squeeze Recursion Pharmaceuticals Short Squeeze Immunocore Short Squeeze Neumora Therapeutics Short Squeeze BioCryst Pharmaceuticals Short Squeeze Novavax Short Squeeze Mesoblast Short Squeeze Vir Biotechnology Short Squeeze LENZ Therapeutics Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ALLO) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALLO Stock Alerts